Analysts Set Rallybio Co. (NASDAQ:RLYB) PT at $10.00

Shares of Rallybio Co. (NASDAQ:RLYB) have been given an average recommendation of “Moderate Buy” by the six brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $10.00.

A number of research analysts have commented on RLYB shares. Evercore ISI reissued an “outperform” rating and set a $15.00 target price on shares of Rallybio in a research report on Monday, August 26th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Rallybio in a research report on Tuesday, October 1st.

Rallybio Price Performance

RLYB stock opened at $1.12 on Monday. The company has a market capitalization of $46.42 million, a PE ratio of -0.60 and a beta of -1.70. Rallybio has a 12 month low of $1.08 and a 12 month high of $4.60. The firm’s 50-day moving average is $1.12 and its 200 day moving average is $1.41.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. The company had revenue of $0.30 million during the quarter. Sell-side analysts forecast that Rallybio will post -1.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Hsbc Holdings PLC acquired a new stake in Rallybio in the 2nd quarter worth approximately $25,000. Acadian Asset Management LLC acquired a new stake in Rallybio in the 1st quarter worth approximately $57,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Rallybio in the 2nd quarter worth approximately $61,000. Almitas Capital LLC acquired a new stake in Rallybio in the 2nd quarter worth approximately $135,000. Finally, Vanguard Group Inc. boosted its stake in Rallybio by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 1,076,771 shares of the company’s stock worth $1,992,000 after purchasing an additional 12,801 shares in the last quarter. Hedge funds and other institutional investors own 90.34% of the company’s stock.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.